Two drugs vs one for PDL1-negative breast cancer
Treatments studied
Part of Cancer, Skin clinical trials.
This trial tests a new combination of two drugs (datopotamab deruxtecan plus durvalumab) against one drug alone (datopotamab deruxtecan) for people with PDL1-negative, triple-negative breast cancer that has spread. The goal is to see if the combination works better.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are a woman aged 18 or older with triple-negative breast cancer that has spread (metastatic).
- Your cancer must be PDL1-negative (a specific score less than 10).
- You have not already had chemotherapy or immunotherapy for advanced breast cancer.
- You have at least one tumor that can be measured on a scan and hasn't been treated with radiation.
- You are generally healthy enough for daily activities (ECOG 0-1) and have adequate organ function.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new drug combination (BL-B01D1 plus an immunotherapy) for people with advanced triple-negative breast cancer who have not had prior treatment for their advanced disease. The goal is to see if the combination works better at shrinking or controlling the cancer.
This trial tests experimental drugs for people with triple-negative breast cancer that came back within 12 months of finishing initial treatment. The goal is to see if these drugs are safe and can shrink or slow the cancer.
This trial is testing whether a new drug combination (Dato-DXd with or without durvalumab) works better than standard chemotherapy plus pembrolizumab for people with a certain type of advanced triple-negative breast cancer that has a protein called PD-L1. The study aims to find a more effective treatment option for this specific group.
This trial studies Dato-DXd (an antibody-drug medicine) in people with triple-negative breast cancer that has spread to the brain. It aims to see how well it controls brain tumors when they are newly found or growing after other treatments.
This trial tests a new two-drug combination (Dato-DXd and an immunotherapy called rilvegostomig) as the first treatment for people with advanced non-squamous lung cancer who have high PD-L1 levels. The goal is to see if this combination works better than current standard options.
This trial tests a new drug, datopotamab deruxtecan, against a standard chemotherapy (docetaxel) for people with advanced non-squamous lung cancer that has gotten worse after previous treatment. It is for those who do not have certain genetic changes (like EGFR, ALK, or ROS1) and whose tumors have a protein called TROP2.
Hear when a new Triple Negative Breast Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.